Arkolith/Insider Trading/ZNTL/Form 4

Lackner Mark

Chief Scientific OfficerZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Feb 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$18K
Net Open-Market Flow
-$18K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2024Sell(S)2K$11.54$18K196K
Feb 1, 2024Grant(A)141K—$0197K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2024Grant(A)141K—$0141K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725160-24-000034) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML